Please assess the completion status of the following clinical trial:

Trial Title: AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy women, ages 18-45~* Body mass index (BMI) ≥18 and ≤32, and weight ≥ 110 lbs.~* Willing to use a non-hormonal method of contraception if at risk of pregnancy, OR have already undergone previous bilateral tubal ligation or hysterectomy~* Willing to refrain from use of alcohol and grapefruit juice from 48 hours prior until completion of each treatment period~Exclusion Criteria:~* Known or suspected pregnancy;~* Lactating women~* Significant skin reaction to transdermal preparations or sensitivity to surgical / medical tape~* Any disease that may worsen under hormonal treatment (cardiovascular, liver, metabolic)~* Use of other contraceptive methods than study medication~* Smokers

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Ortho-Cyclen® (Type: ACTIVE_COMPARATOR): Ortho-Cyclen® is a comparator drug intervention
- AG200-15 (Type: EXPERIMENTAL): AG200-15 is an investigational transdermal contraceptive delivery system that is a drug intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).